The most common grade @-@ adverse events were neutropenia ( @ -LSB- @ % -RSB- in the pazopanib group vs one -LSB- @ % -RSB- in the paclitaxel group ) , fatigue ( four -LSB- @ % -RSB- vs two -LSB- @ % -RSB- ) , leucopenia ( four -LSB- @ % -RSB- vs one -LSB- @ % -RSB- ) , hypertension ( three -LSB- @ % -RSB- vs none -LSB- @ % -RSB- ) , raised aspartate aminotransferase or alanine aminotransferase ( three -LSB- @ % -RSB- vs none ) , and anaemia ( two -LSB- @ % -RSB- vs five -LSB- @ % -RSB- ) .